
LSTA Stock Forecast & Price Target
LSTA Analyst Ratings
Bulls say
Lisata Therapeutics Inc. has demonstrated notable progress with its lead candidate, certepetide, as evidenced by positive preliminary data from Cohort A presented at ASCO GI. The results indicate a favorable trend in overall survival, highlighting four complete responses within the certepetide treatment group, which underscores the potential efficacy of the drug. Additionally, Cohort B data suggests that administering a second dose of certepetide may further enhance progression-free survival (PFS) and overall response rate (ORR) for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), reflecting the strong therapeutic promise of the investigational treatment.
Bears say
Lisata Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to the potential for failed or inconclusive clinical trials that could derail the progress of its investigational drug, certepetide. Additionally, the company's reliance on securing adequate funding to advance its drug development is a concern; any shortfall in funding could hinder its operational capabilities. The overall financial health of the company is further jeopardized by these uncertainties, thereby casting doubt on its ability to achieve favorable valuation outcomes.
This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LSTA Analyst Forecast & Price Prediction
Start investing in LSTA
Order type
Buy in
Order amount
Est. shares
0 shares